Mutual Advisors LLC Acquires 12,148 Shares of Pfizer Inc. $PFE

Key Points

• Mutual Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE) by 5.5%, acquiring an additional 12,148 shares, bringing their total holdings to 233,541 shares valued at approximately $5.79 million.
• Pfizer reported a quarterly earnings per share (EPS) of $0.78, surpassing expectations and showing a 10.3% growth in revenue year-over-year, totaling $14.65 billion.
• The company recently announced a quarterly dividend of $0.43, with a current dividend yield of 7.1% and a payout ratio of 91.49%.

Mutual Advisors LLC boosted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 233,541 shares of the biopharmaceutical company's stock after buying an additional 12,148 shares during the quarter. Mutual Advisors LLC's holdings in Pfizer were worth $5,789,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Bessemer Group Inc. raised its holdings in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK raised its holdings in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after purchasing an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new position in Pfizer during the 1st quarter worth approximately $8,283,000. Westbourne Investments Inc. bought a new position in Pfizer during the 1st quarter worth approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. raised its holdings in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock worth $927,000 after purchasing an additional 18,200 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

NYSE PFE opened at $24.39 on Thursday. The company has a fifty day simple moving average of $24.89 and a 200 day simple moving average of $24.13. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.82. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market cap of $138.69 billion, a P/E ratio of 12.98, a PEG ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm posted $0.60 EPS. Pfizer's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on PFE shares. Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a report on Friday, October 10th. Bank of America raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a "neutral" rating in a report on Friday, October 3rd. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. UBS Group restated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.35.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.